Back to Search
Start Over
Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction
- Source :
-
European Journal of Cancer . Nov2005, Vol. 41 Issue 17, p2682-2689. 8p. - Publication Year :
- 2005
-
Abstract
- Abstract: The aim of this study was to assess the efficacy and adverse effects of 2-chlorodeoxyadenosine (2-CdA) and cytosine arabinoside (Ara-C) in children with refractory Langerhans cell histiocytosis (LCH) and haematopoietic dysfunction. Ten patients, with a median age at diagnosis of 0.5 years, were enrolled in this study. Treatment comprised at least two courses of Ara-C (1000mg/m2/d) and 2-CdA (9mg/m2/d) administered for 5d every 4 weeks; subsequent median follow-up was 2.8 years (range 0.03–6.4 years). Among the 7 patients who received at least two courses of therapy, disease activity decreased in 6 patients, and control of disease was achieved in all patients after a median delay of 5.5 months. All patients suffered World Health Organisation (WHO) grade 4 haematological toxicity. Two septic deaths occurred shortly after administration of the first course of 2-CdA/Ara-C; a third patient was withdrawn from the trial after the first course and subsequently died following haematopoietic stem cell transplantation. This series is small, but we conclude that 2-CdA and Ara-C combined chemotherapy probably has major activity in childhood refractory Langerhans cell histiocytosis. [Copyright &y& Elsevier]
- Subjects :
- *DENDRITIC cells
*DRUG therapy
*STEM cells
*BONE marrow cells
Subjects
Details
- Language :
- English
- ISSN :
- 09598049
- Volume :
- 41
- Issue :
- 17
- Database :
- Academic Search Index
- Journal :
- European Journal of Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 19102102
- Full Text :
- https://doi.org/10.1016/j.ejca.2005.02.007